GHK-Cu and Tissue Repair: From Preclinical Research to Human Trials

Tissue-remodeling background

GHK enters the wound literature through remodeling, not through an approved wound-healing drug. Reviews describe a human tripeptide and, separately, the copper complex in a story of matrix, fibroblasts, and tissue.^1,2

This page follows that line to the clinical registry. It is not the wrinkle page and not a general inventory of every trial. The hub is the GHK-Cu hub.

Remodeling, in the laboratory, covers matrix synthesis, enzymes that trim it, and sometimes angiogenesis. Those are tissue hypotheses. “Heals wounds,” used as an established fact, is marketing language.

“Repair” has to be read as a laboratory word. In a paper it can mean a histologic change, experimental wound closure, or a matrix marker. On a commercial page it usually means a visible promise. This cluster stays with the first sense.

Preclinical evidence

The cell work includes human fibroblasts in culture and sulfated glycosaminoglycan synthesis in the presence of the tripeptide–copper complex. That places GHK-Cu in the matrix biology researchers associate with experimental repair.³

Reviews also collect animal models and accounts of wound, angiogenesis, and remodeling. Those sources are useful for mapping why a topical trial exists now. They are not, themselves, that trial.^1,2

The 2026 systematic review, though focused on aesthetic medicine, shows the same imbalance: 18 of 20 included studies were preclinical. The weight of the literature is not in people.⁴

Limits of translation

• An animal wound model does not fix an endpoint on adult human skin.
• A fibroblast in culture is not a clinical wound bed.³
• A paper’s formulation is not a commercial gel, and a trial gel is not a “copper peptide” serum.
• The topical route of a wound study does not become evidence for an injectable route.

Translation here means: the step from an experimental system to a clinical question is still open. The 2026 review asks for larger trials and standardized delivery methods for that reason.⁴

Historical human claims, where they can be verified

Conservatism is required. Older reviews mention clinical observations or historical uses. Those mentions are not treated here as several independent randomized trials.¹

The human topical trial that can be cited as a primary publication in this cluster is Miller 2006. It was a topical regimen after CO2 laser, not an acute punch-biopsy wound trial, and its objective outcomes did not show significant advantages. It is not used as proof that GHK-Cu “heals wounds.”⁶

If a secondary source claims a wound trial that cannot be identified as a primary publication in this system, the citation is not created.

Active Phase 2 trial

A recruiting trial is not a demonstrated treatment. The registry documents that a controlled human investigation is underway. It does not establish the outcome.

What the study is designed to test

The registry concept: healthy adults receive standardized small punch-biopsy wounds. A topical GHK-Cu gel is compared with vehicle. It is a controlled acute-wound design, not a wrinkle study and not an injectable compounding study.⁵

That is a concrete clinical question: does a topical gel, versus its vehicle, change healing of a small experimental wound? Until results exist, the answer is not in the registry.

This cluster does not reproduce the protocol’s application schedule as an instruction. Describing the design is not telling a reader how to treat a wound.

A punch-biopsy wound in a healthy adult is a controlled experimental model. It is not a chronic ulcer, not a large surgical wound, and not the skin of a patient with comorbidity. Even if the trial later posts results, that scope will still be the first thing to read.

The gel’s topical route is also not mixed with injectable compounding discussion. A gel-versus-vehicle registry record does not inform the safety of an injectable preparation, and an FDA note on that route does not anticipate the CuHeal outcome.

No results posted

As of 1 September 2026, no efficacy results are posted on ClinicalTrials.gov for NCT07437586. The registry last-update date we use is 27 February 2026. Those dates are not updated automatically.⁵

When results exist, the primary publication will need to be read — size, endpoints, formulation — not the mere fact that the trial existed. Existing in a registry is the floor, not the proof.

The full human inventory is in human clinical studies. Skin and wrinkle evidence, a different question, is in skin clinical evidence.